We all know that partnerships are the lifeblood of the biopharma industry. Understanding what makes them work can mean the difference between disaster and blockbuster success for biotech and pharma…
B&M: So David, let’s start by you just telling me a little bit about your VC firm, what is your history and your key focus? DG: Index was founded in 1996. In the…
We caught up with Dr Eliot Forster, CEO of Creabilis Therapeutics and the Executive Chair of MedCity to talk us through the last couple of months progress since the launch.…
This is the fourth of 4 weekly Polls hosted throughout July that will accompany the August edition of Drugs&Dealers Magazine ‘Lost in Translation: Tech Transfer and Start-up Capital’. This poll reviews the cash…
B&M: Nigel you’re the Chief Investment Officer within Imperial Innovations and responsible for the Group’s investment activities, but what does that equate to on a day-to-day basis?…
B&M: Lucy, can you give our readers a brief overview of the primary markets role at the London Stock Exchange and specifically your role here? LT: I’m…
This is the third of 4 weekly Polls hosted throughout July that will accompany the August edition of Drugs&Dealers Magazine ‘Lost in Translation: Tech Transfer and Start-up Capital’. The results from this Poll will…
How to Raise Capital: What Can We Learn from Skyepharma? B&M: Do you want to start by quickly giving us your company story, your elevator pitch? PG: The business is…
What is keeping biotech CEOs awake at night? Terry O’Dwyer, Co-CEO, Biotech and Money: What is keeping you awake at night? Tim Mitchell, CEO, Sareum: The challenge is to…
